ST2：心力衰竭的新型生物标志物。
ST2: a novel biomarker for heart failure.
机构信息
Cardiology Division, Massachusetts General Hospital, 32 Fruit Street, Yawkey 5984, Boston, MA 02114, USA.
出版信息
Expert Rev Mol Diagn. 2010 May;10(4):459-64. doi: 10.1586/erm.10.25.
ST2, an IL-1 receptor family member with transmembrane (ST2L) and soluble (sST2) isoforms, was originally described in the context of inflammatory and autoimmune diseases. However, after the identification of IL-33 as the functional ligand for ST2, and conceptualization of the role of ST2/IL-33 signaling in cardiac remodeling, sST2 has emerged as a novel cardiovascular biomarker for the presence of ventricular biomechanical overload. Concentrations of sST2 have been implicated in the presence and severity of heart failure with particular value for prognostication. We will review the use of sST2 as a prognostic marker in heart failure, including present and future directions in this exciting area.
ST2，IL-1 受体家族成员，具有跨膜（ST2L）和可溶性（sST2）两种形式，最初在炎症和自身免疫性疾病的背景下被描述。然而，在鉴定出 IL-33 是 ST2 的功能配体，并将 ST2/IL-33 信号在心脏重构中的作用概念化后，sST2 已成为心室力学过载存在的新型心血管生物标志物。sST2 的浓度与心力衰竭的存在和严重程度有关，对预后具有特别重要的价值。我们将回顾 sST2 作为心力衰竭预后标志物的应用，包括这一令人兴奋领域的当前和未来方向。
Zotero 插件